The Use of Betaine HCl to Enhance Dasatinib Absorption in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria

Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update

(2014) Ralph-Steven Wedemeyer et al.   DRUG SAFETY

Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

(2013) Enrique Grande et al.   ADVANCES IN THERAPY

Proton Pump Inhibitor Prescriptions and Subsequent Use in US Veterans Diagnosed with Gastroesophageal Reflux Disease

(2013) Andrew J. Gawron et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Gastric Reacidification with Betaine HCl in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria

(2013) Marc R. Yago et al.   MOLECULAR PHARMACEUTICS

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

(2013) Gillian S. Smelick et al.   MOLECULAR PHARMACEUTICS

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

(2012) N R Budha et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Impact of Acid Suppression on Upper Gastrointestinal pH and Motility

(2010) Whitney Michalek et al.   DIGESTIVE DISEASES AND SCIENCES

Effect of Low-Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple-Dose Atazanavir With Ritonavir in Healthy Subjects

(2010) Li Zhu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical pharmacokinetics of tyrosine kinase inhibitors

(2009) Nielka P. van Erp et al.   CANCER TREATMENT REVIEWS

Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects

(2009) Timothy Eley et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Use of Experimental Design Principles in Dissolution Method Development: Development of a Discriminating Dissolution Method for Sprycel Film-Coated Tablets

(2009) William P. Fish et al.   Journal of Pharmaceutical Innovation

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

(2008) M. Brave et al.   CLINICAL CANCER RESEARCH